Inventor · disambiguated record
Elisabetta Bianchi
Also filed as: BIANCHI ELISABETTA
30 granted patents·25 pending applications·128 citations·filing 1990–2025
95Inventor score
Files withMERCK SHARP & DOHME11MERCK SHARP & DOHME LLC11SANOFI SA6BIANCHI ELISABETTA5JANSSEN BIOTECH INC5
Top patents by PatentIndex Score
55 records- 0192US7928058B2Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the compositionMERCK SHARP & DOHME·Filed 2007·Granted Apr 19, 2011·37 cites·18 claims
- 0290US11773150B2Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptorsMERCK SHARP & DOHME LLC·Filed 2020·Granted Oct 3, 2023·2 cites·7 claims
- 0387US10493125B2Co-agonists of the glucagon and GLP-1 receptorsMERCK SHARP & DOHME·Filed 2016·Granted Dec 3, 2019·4 cites·20 claims
- 0486US8969294B2Glucagon/GLP-1 receptor co-agonistsBIANCHI ELISABETTA·Filed 2012·Granted Mar 3, 2015·14 cites·12 claims
- 0585US11530244B2Cyclic polypeptides for PCSK9 inhibitionMERCK SHARP & DOHME LLC·Filed 2019·Granted Dec 20, 2022·6 cites·15 claims
- 0685US10961295B2Modified lipidated Relaxin B chain peptides and their therapeutic useSANOFI SA·Filed 2019·Granted Mar 30, 2021·2 cites·23 claims
- 0784US11492385B2Long-acting co-agonists of the glucagon and GLP-1 receptorsMERCK SHARP & DOHME·Filed 2020·Granted Nov 8, 2022·1 cites·33 claims
- 0884US10793615B2Long-acting co-agonists of the glucagon and GLP-1 receptorsMERCK SHARP & DOHME·Filed 2016·Granted Oct 6, 2020·4 cites·17 claims
- 0983US11427616B2PCSK9 antagonist compoundsMERCK SHARP & DOHME LLC·Filed 2019·Granted Aug 30, 2022·3 cites·48 claims
- 1082US12018057B2Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesJANSSEN BIOTECH INC·Filed 2021·Granted Jun 25, 2024·1 cites·10 claims
- 1180US7811577B2Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activityMERCK SHARP & DOHME·Filed 2005·Granted Oct 12, 2010·5 cites·31 claims
- 1279US10988524B2Modified relaxin B chain peptides and their therapeutic useSANOFI SA·Filed 2019·Granted Apr 27, 2021·2 cites·20 claims
- 1379US2025206781A1Pcsk9 antagonist compoundsMERCK SHARP & DOHME LLC·Filed 2024·Application pending·0 cites
- 1476US10413593B2Co-agonists of the glucagon and GLP-1 receptorsMERCK SHARP & DOHME·Filed 2015·Granted Sep 17, 2019·2 cites·30 claims
- 1575US2024218042A1Modified lipidated relaxin b chain peptides and their therapeutic useSANOFI SA·Filed 2023·Application pending·0 cites
- 1674US10988523B2Modified lipidated Relaxin B chain peptides and their therapeutic useSANOFI SA·Filed 2019·Granted Apr 27, 2021·2 cites·20 claims
- 1773US12209145B2PCSK9 antagonist compoundsMERCK SHARP & DOHME LLC·Filed 2022·Granted Jan 28, 2025·0 cites·29 claims
- 1873US9593155B2Oxyntomodulin analogsMERCK SHARP & DOHME·Filed 2015·Granted Mar 14, 2017·2 cites·10 claims
- 1973US8629101B2Cholesterol derivatives of inhibitors of viral fusionPESSI ANTONELLO·Filed 2008·Granted Jan 14, 2014·3 cites·3 claims
- 2073US7744887B2Human antibodies interacting with HIV gp41MERCK & CO INC·Filed 2005·Granted Jun 29, 2010·1 cites·11 claims
- 2172US2024150405A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 2272US2024383954A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 2369US12012468B2Cyclic polypeptides for PCSK9 inhibitionMERCK SHARP & DOHME LLC·Filed 2022·Granted Jun 18, 2024·0 cites·15 claims
- 2467US11725036B2Modified lipidated relaxin B chain peptides and their therapeutic useSANOFI SA·Filed 2020·Granted Aug 15, 2023·0 cites·3 claims
- 2566US8268779B2Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the compositionSINHA ROY RANABIR·Filed 2011·Granted Sep 18, 2012·2 cites·14 claims
- 2666US2025381324A1Cd31 mimetic coating for endovascular stentINST NAT SANTE RECH MED·Filed 2022·Application pending·0 cites
- 2765US5196512ASynthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use in the development of synthetic vaccinesENIRICERCHE SPA·Filed 1990·Granted Mar 23, 1993·28 cites·1 claims
- 2862US11932705B2Cyclic polypeptides for PCSK9 inhibitionMERCK SHARP & DOHME LLC·Filed 2022·Granted Mar 19, 2024·0 cites·13 claims
- 2962US6995177B1HCV NS3 protease inhibitorsANGELETTI P IST RICHERCHE BIO·Filed 2000·Granted Feb 7, 2006·2 cites·23 claims
- 3060US2023406885A1Cyclic peptides for trapping interleukin-1 betaMERCK SHARP & DOHME LLC·Filed 2023·Application pending·0 cites
- 3158US2024352073A1Bicyclic peptide inhibitors of interleukin-23 receptorJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 3258US2022128572A1Immunological signatures and parameters predicting therapeutic responses to anti-tnf therapyPASTEUR INSTITUT·Filed 2022·Application pending·0 cites
- 3358US2010075907A1Neuromedin u receptor agonists and uses thereofMARSH DONALD J·Filed 2009·Application pending·0 cites
- 3457US2024409598A1Peptide inhibitors of interleukin-23 receptorJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 3556US2023105982A1Insulin-incretin conjugatesMERCK SHARP & DOHME·Filed 2021·Application pending·0 cites
- 3654US2023270825A1Stapled olefin co-agonists of the glucagon and glp-1 receptorsMERCK SHARP & DOHME LLC·Filed 2020·Application pending·0 cites
- 3754US2023063794A1Stapled triazole co-agonists of the glucagon and glp-1 receptorsMERCK SHARP & DOHME LLC·Filed 2020·Application pending·0 cites
- 3852US11505575B2Cyclic polypeptides for PCSK9 inhibitionMERCK SHARP & DOHME LLC·Filed 2019·Granted Nov 22, 2022·0 cites·23 claims
- 3952US2025243255A1Crf2 receptor agonists and their use in therapySANOFI SA·Filed 2021·Application pending·0 cites
- 4051US2023285514A1Stapled lactam co-agonists of the glucagon and glp-1 receptorsBIANCHI ELISABETTA·Filed 2020·Application pending·0 cites
- 4150US2007244048A1Neuromedin U receptor agonists and uses thereofMARSH DONALD J·Filed 2007·Application pending·0 cites
- 4250US2014094405A1Cholesterol derivatives of inhibitors of viral fusionANGELETTI P IST RICHERCHE BIO·Filed 2013·Application pending·0 cites
- 4349US2004223976A1Influenza virus vaccineFiled 2004·Application pending·0 cites
- 4449US2009104220A1Method to Make a Peptide-Carrier Conjugate with a High ImmunogenicityBIANCHI ELISABETTA·Filed 2004·Application pending·0 cites
- 4548US11249090B2Immunological signatures and parameters predicting therapeutic responses to anti-TNF therapyPASTEUR INSTITUT·Filed 2016·Granted Feb 15, 2022·0 cites·22 claims
- 4645US11306125B2PCSK9 antagonists bicyclo-compoundsMERCK SHARP & DOHME·Filed 2019·Granted Apr 19, 2022·0 cites·15 claims
- 4745US10800826B2Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptorsMERCK SHARP & DOHME·Filed 2016·Granted Oct 13, 2020·0 cites·10 claims
- 4843US11566057B2Long-acting co-agonists of the glucagon and GLP-1 receptorsMERCK SHARP & DOHME·Filed 2018·Granted Jan 31, 2023·0 cites·24 claims
- 4943US2011301079A1Neuromedin u receptor agonists and uses thereofMARSH DONALD J·Filed 2008·Application pending·0 cites
- 5043US2025296959A1B7-h3 targeting peptides and constructs thereofMARIANA ONCOLOGY INC·Filed 2025·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Elisabetta Bianchi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →